Buradasınız

Anasayfa » Content

Hemodiyaliz Hastalarında HCV Enfeksiyonunun Serum Lipid Profili Üzerine Etkileri

The Effects of HCV Infection on Serum Lipid Profile in Hemodialysis Patients

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2010
DOI: 
10.5262/tndt.2010.1001.06

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Objective: We aimed to investigate effects of hepatitis C virus infection on serum lipid profile in hemodialyzed patients. Method: The serum lipid profile was determined in 108 patients who had been on regular hemodialysis for at least two months. Serum total cholesterol (TC), triglyceride (TG), HDL (high density lipoprotein), VLDL (very low density lipoprotein) and LDL (low density lipoprotein) levels were compared between two groups. Result s: The study included 55 HCV-negative (%58 male) and 53 HCV-positive (%64 male) hemodialysed patients. Mean age was 43±16 years in the HCV-negative group and 43±14 years in the HCV-positive group. There were no significant differences between the two groups with respect to age and gender. Mean duration of HD was 20±16 months in the HCV (-) group and 50±32 months in the HCV (+) group. Mean hemodialysis time was longer in HCV (+) patients than HCV (-) patients (p<0.0001). Mean serum TC (129±27 vs 148±42 mg/dL; p=0.006), TG (137±55 vs 162±64 mg/dL; p=0.032), and HDL levels (32±11 vs 36±11 mg/dL; p=0.036) were significantly lower in the HCVpositive group than in the HCV-negative group. Mean serum LDL and VLDL levels were similar in the two groups. Although we did not find a statistical difference between serum lipid levels and ALT levels; there was a statistically significant correlation between serum AST level and TC, TG, and VLDL-c levels. Serum TC, VLDL levels were significantly higher in patients with AST >30 iu/dL than in patients with AST <30 iu/dL. Conclusion: The present study suggests that HCV infection is associated with lower TC, TG and VLDL-c levels in hemodialysed patients. An increase in serum AST levels was associated with a decrease in lipid levels.
Bookmark/Search this post with
Abstract (Original Language): 
Amaç: Hemodiyaliz (HD) hastalarında hepatit C virüs (HCV) enfeksiyonunun serum lipid düzeyleri üzerine etkilerini araştırmak. gereç ve yöntem: Çalışmaya iki aydan uzun süredir HD tedavisi gören 108 hasta dahil edildi. Hastalar HCV pozitif ve negatif omak üzere iki gruba ayrıldı. Her iki grubun serum total kolesterol (TK), trigliserid (TG), yüksek yoğunluklu lipoproteinler (HDL), düşük yoğunluklu lipoprotein (LDL), ve çok düşük yoğunluklu lipoprotein (VLDL) düzeyleri karşılaştırıldı. Bulgular: Olgularımızın 55’i (%58 E) anti-HCV (-) ve 53’ü (%64 E) anti-HCV(+) idi. Anti- HCV(-) grubun yaş ortalaması 43±16 yıl ve HD süresi 20±16 ay iken anti-HCV(+) grupta bu değerler sırası ile 43±14 yıl ve 50±32 ay idi. Yaş ve cinsiyet yönünden her iki grup benzer iken HCV(+) grupta HD süresi daha uzun idi (p<0,0001). Hastaların TK düzeyleri karşılaştırıldığında anti-HCV(-) grupta 148±42 mg/dl iken anti-HCV(+) grupta 129±27 mg/dl idi. Gruplar arasındaki fark anlamlı idi (p=0,006). Anti-HCV negatif grupta TG düzeyleri 162±64 mg/dl iken anti-HCV pozitif grupta 137±55 mg/dl saptandı. Her iki grup arasındaki fark istatistiksel olarak anlamlı bulundu (p=0,032). Anti-HCV(-) grupta ortalama HDL düzeyleri 36±11mg/dl iken anti-HCV(+) grupta 32±11 mg/dl idi. Her iki grup arasındaki fark istatistiksel olarak anlamlı idi (p=0,036). Her iki grubun hem LDL hem de VLDL düzeyleri arasında istatistiksel olarak anlamlı fark saptanmadı. Çalışmamızda, serum ALT düzeyleri ile serum lipid düzeyleri arasında herhangi bir istatistiksel ilişki saptanmazken; serum AST düzeyleri ile TK, TG ve HDL düzeyleri arasında anlamlı korelasyon saptandı. Serum AST değeri >30 iü/dl ve <30 iü/dl olan hastalar karşılaştırıldığında ortalama serum TK, TG ve VLDL düzeyleri, AST >30 olan grupta istatistiksel olarak anlamlı derecede daha düşük saptandı. SONUÇ: Hemodiyalize giren HCV (+) hastalarda serum TK, TG ve HDL düzeyleri HCV (-) hastalara göre daha düşüktür. Serum AST düzeyleri arttıkça TK, TG ve VLDL düzeyleri azalma eğiliminde idi.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_19_pp_40-45.pdf
  • 1
40-45
  • Turkish

REFERENCES

References: 

1. Wan RK, Mark PB, Jardine AG: The cholesterol paradox is
flawed; cholesterol must be lowered in dialysis patients. Semin
Dial 2007; 20: 504-509
2. Syrjanen J, Mustonen J, Pasternack A: Hypertryglyceridaemia
and hyperuricaemia are risk factors for progression of Ig A
nephropathy. Nephrol Dial Transplant 2000; 15:34-42
3. Sezer S, Tutal E, Aldemir D, Türkoglu S, Demirel OU, Afsar B,
Ozdemir FN, Haberal M: Hepatitis C infections in hemodialysis
patients: Protective against oxidative stress. Transplant Proc
2006; 38: 406-410
4. Moriya K, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T,
Yotsuyanagi H, Iino S, Kimura S, Koike K. Serum lipid profile
of patients with genotype 1b hepatitis C viral infection in Japan.
Hepatol Res 2003; 25: 371-376
Şahin İ ve ark: Hemodiyaliz Hastalarinda HCV
Enfeksiyonunun Serum Lipid Profili Üzerine Etkileri
Cilt/Vol: 19, No: 1, 2010, Sayfa/Page: 40-45
44
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
45
5. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic
M, Osterreicher C, Mueller C, Gangl A, Ferenci P: Hepatocellular
fat accumulation and low serum cholesterol in patients infected
with HCV-3a. Am J Gastroenterol 2002; 97: 2880-2885
6. Serfaty L, Andreani T, Giral P, Carbonell N, Chaozuilleres O,
Poupon R: Hepatitis C virus induced hypobetalipoproteinemia: A
possible mechanism for steatosis in chronic hepatitis C. J Hepatol
2001; 34: 428-434
7. Polgreen PM, Fultz SL, Justice AC, Wagner DJ, Diekema
DJ, Rabeneck L, Weissman S,Stapleton JT: Association of
hypocholesterolemia with hepatitis C virus infection in HIVinfected
people. HIV Med 2004; 5: 144-150
8. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M: Blood lipids
of patients with chronic hepatitis: Differences related to viral
etiology. Clin Chim Acta 1997; 261: 159-165
9. Dai CY, Chuang WL, Ho CK, Hsieh MY, Huang JF, Lee LP, Hou
NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY,
Yu ML: Associations between hepatitis C viremia and low serum
triglyceride and cholesterol levels: A community based study. J
Hepatol 2008; 49: 9-16
10. Friedwald WT, Levy RI, Fredrickson DS: Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of preparative ultracentrifuge. Clin Chem 1972; 18:
499-502
11. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM:
Changes in serum lipoprotein profile during interferon therapy in
chronic hepatitis C Am J Gastroenterol 2001; 96: 2468–2472
12. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, Hamamoto
N, Ishihara S, Watanabe M, Kinoshita Y: Changes in serum lipid
concentrations in patients with chronic hepatitis C virus positive
hepatitis responsive or non-responsive to inferon therapy. J
Gastroenterol Hepatol 2005; 20: 204-208
13. Ocak S, Duran N, Kaya H, İmir İ: Seroprevalence of hepatitis
C in patients with type 2 diabetes mellitus and non-diabetics on
haemodialysis. Int J Clin Pract 2006; 60: 670-674
14. Sahin I, Arabaci F, Sahin HA, Ilhan M, Ustun Y, Mercan R,
Eminov L: Does hepatitis C virus infection increase hematocrit
and hemoglobin levels in hemodialyzed patients? Clin Nephrol
2003; 60:401-404
15. Yildirim B, Durak H, Ozaras R, Canbakan B, Ozkan P, Ozbay G,
Senturk H: Liver steatosis in hepatitis C positive hemodialysis
patients and factors affecting IFN-2a treatment. Scand J
Gastroenterol 2006; 41: 1235-1241
16. Chan TM, Lau JY, Wu PC, Lai CL, Lok AS, Cheng IK: Hepatitis
C virus genotypes in patients on renal replacement therapy.
Nephrol Dial Transplant 1998; 13: 731-734
17. Fabrizi F, Lunghi G, Andrulli S, Pagliari B, Mangano S, Faranna
P, Pagano A, Locatelli F: Influence of hepatitis C virus (HCV)
viraemia upon serum aminotransferase activity in chronic dialysis
patients. Nephrol Dial Transplant 1997; 12: 1394-1398
18. Siagris D, Christofidou M, Teocharis GJ, Pagoni N, Papadimitriou
C, Lekkou A, Thomopoulos K, Starakis I, Tsamandas AC,
Labropoulou- Karatza C: Serum lipid pattern in chronic hepatitis
C: Histological and virological correlations. J Viral Hepat 2006;
13: 56-61
19. Chiang MC, Yang Y, Chang CC, Wen YK, Wu HC, Kang IC:
The uremic dyslipidemia: CAPD compared with HD. Acta
Nephrologica 2001; 15: 105-110
20. Ambrosch A, Domroese U, Westphal S, Dierkes J, Augustin W,
Neumann KH, Luley C: Compositional and functional changes
of low-density lipoprotein during hemodialysis in patients with
ESRD. Kidney Int 1998; 54: 608-617
21. Jarmay K, Karacsony G, Nagy A, Schaff Z: Changes in serum
lipid metabolism in chronic hepatitis C. World J Gastroenterol
2005; 11: 6422-6428
22. Marzouk D, Sass J, Bakr I, El-Hosseiny M, Abdel-Hamid M,
Rekacewicz C, Chaturvedi N, Mohamad MK, Fontanet A:
Metabolic and cardiovascular risk profile and HCV infection in
rural Egypt. Gut 2007; 56: 1105-1110
23. Hsu CS, Liu CJ, Liu CH, Wang CC, Chen CL, Lai MY, Chen PJ,
Kao JH, Chen DS. Metabolic profiles in patients with chronic
hepatitis C: A case control study. Liver Int 2008; 28: 271-277
24. Pedro-Botet J, Senti M, Rubies-Prat J, Pelegri A, Romero R:
When to treat the dyslipidaemia of patients with chronic renal
failure on haemodialysis? A need to define spesific guidelines.
Nephrol Dial Transplant 1996; 11: 308-313
25. Vaziri ND: Dyslipidemia of chronic renal failure: the nature,
mechanisms, and potential consequences. Am J Physiol Renal
Physiol 2006; 290: 262-272
26. Kapadia SB, Barth H, Baumert T, McKeating JA, Chisari FV:
Initiation of hepatitis V infection is dependent on cholesterol and
cooperativity between CD81 and scavenger receptor B type 1. J
Virol 2007; 81: 374-383

Thank you for copying data from http://www.arastirmax.com